Skip to main content
TipRanks
Go Ultimate75% OFF

Beam Therapeutics (BEAM) Q4 2025 Earnings Report

2,361 Followers

BEAM Q4 2025 EPS Results

Actual EPS
$2.33
Consensus EPS
-$1.01
Beat/Miss
Beat by +$3.34
One Year Ago EPS
-$1.09

BEAM Q4 2025 Revenue Results

Actual Revenue
$114.11M
Expected Revenue
$11.67M
Beat/Miss
Beat by +$102.44M
YoY Revenue Growth
+279.52%

Earnings Announcement Details

Quarter
Q4 2025
Date
02/24/2026
Time
Before Open
Conference Call
Tuesday, February 24, 2026
BEAM Upcoming Earnings

Beam Therapeutics's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q4 2025 Earnings Call Audio

BEAM Q4 2025 Earnings Call
0:00 / 0:00

Q4 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2025 Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 24, 2026|% Change Since:-26.09%|
Earnings Call Sentiment|Positive

The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.

Company Guidance

Beam provided clear program and financial guidance: Beam plans to file the BEAM‑304 IND in 2026 and initiate an open‑label, single‑ascending‑dose Phase I/II in R408W, expects to report updated BEAM‑302 Phase I/II data and a pivotal plan this quarter and to submit the risto‑cel BLA as early as year‑end 2026, and also expects to report initial BEAM‑301 GSDIa data, complete the BEAM‑103 healthy volunteer study and advance in‑vivo HSC editing during 2026. Financially, Beam ended 2025 with $1.25 billion in cash/cash equivalents/marketable securities and announced a Sixth Street facility up to $500 million ( $100M funded at close, up to $300M tied to regulatory/clinical/commercial milestones, plus $100M subject to mutual agreement over a 7‑year term), with a minimum draw of $200M expected to extend runway into mid‑2029 and principal repayment due early 2033. Key program metrics highlighted include two BEAM‑304 candidates that could address nearly half of ~20,000 U.S. PKU patients, preclinical single‑dose (0.3 mg/kg) LNP results that normalized plasma phenylalanine below the 360 µM therapeutic threshold by day 7 in R408W and a second mutation model, and recognition of >1,000 PAH variants worldwide supporting an umbrella/multi‑variant IND approach.

  • New PKU Program (BEAM-304) Initiated and Rapidly AdvancedBeam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
  • Strong Preclinical Efficacy for BEAM-304Preclinical data in mouse models showed rapid and robust plasma phenylalanine (Phe) reductions after a single dose (0.3 mg/kg). In animal studies Phe was reduced below the therapeutic threshold by day 7 (and in a separate humanized model normalized by 48 hours), with a predictable dose–response between on-target liver editing and Phe reduction.
  • Regulatory Engagement and Innovative Trial Design SupportBeam reported productive pre-IND interactions with FDA and substantive discussions supporting a platform/umbrella approach (multiple mutation-specific editors in a single IND) and the ability to add new variants via rapid IND amendments using in vitro data, potentially enabling faster addition of mutation-specific editors.
  • LNP Delivery Expertise and Manufacturing CapabilityBeam emphasized internally developed LNP delivery and optimization expertise, including proprietary ionizable lipids and internal GMP manufacturing capacity in North Carolina, enabling outpatient IV dosing, titratability and redoseability for liver-directed programs.
  • Strategic Non-Dilutive Financing to Strengthen Balance SheetBeam entered a long-term financing facility with Sixth Street providing up to $500 million: $100M funded at close, up to $300M tied to milestones, and an additional $100M subject to agreement. Repayment of principal is due in early 2033.
  • Healthy Cash Balance and Extended RunwayBeam ended 2025 with $1.25 billion in cash, cash equivalents and marketable securities. With the anticipated minimum draw of $200M from the Sixth Street facility, management expects runway to extend into mid-2029 to support pipeline execution and anticipated commercialization activities.
  • Clear Development Milestones and Pipeline MomentumNear-term expectations include BEAM-302 pivotal planning update (alpha-1 antitrypsin deficiency) this quarter, potential risto-cel BLA submission as early as year-end, IND filing for BEAM-304 in 2026, initial BEAM-301 data in GSDIa, completion of BEAM-103 healthy volunteer study, and continued in vivo HSC editing work.
  • Clinical Need and Market Opportunity QuantifiedPKU: ~20,000 individuals in the U.S.; regulatory precedent accepts blood Phe reduction as an endpoint for full approval in U.S./EU. Clinical data cited: ~30% of R408W patients had lifetime average Phe above recommended maximum; only ~25% of adult PKU patients maintain Phe <360 µM; enzyme replacement therapy reaches target in ~60% of patients after 1–2 years.

BEAM Earnings History

BEAM earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)-1.25-2.33――
Nov 03, 20262026 (Q3)-1.16-1.28-1.1-16.36% (-0.18)
Aug 04, 20262026 (Q2)-1.11-1.18-1-18.00% (-0.18)
May 07, 20262026 (Q1)-1.03-0.91-1.2426.61% (+0.33)
Feb 24, 20262025 (Q4)-1.012.33-1.09313.76% (+3.42)
Nov 04, 20252025 (Q3)-1.04-1.10-1.175.98% (+0.07)
Aug 05, 20252025 (Q2)-1.11-1.00-1.119.91% (+0.11)
May 06, 20252025 (Q1)-1.18-1.24-1.21-2.48% (-0.03)
Feb 25, 20252024 (Q4)-1.23-1.091.73-163.01% (-2.82)
Nov 05, 20242024 (Q3)-1.18-1.17-1.224.10% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed